Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Post by Slimchangeon Mar 03, 2021 1:58pm
69 Views
Post# 32706444

ARISTOTLE

ARISTOTLE

it's a waiting game to see how much money they made Q4 to give shareholders confidence in this company leading up to the release of their revolutionary multi detection liquid biopsy cancer test detecting and discriminating 10 cancers with 99% accuracy. 

[Bladder(97/98), Nasopharyngeal(100/100), Colorectal(94/88), Stomach(100/99), Cervical(100/98), Endometrial(100/99), Breast(100/97), Ovarian(97/99), Liver(100/99), Prostate(95/97)] (% ability to detect the cancer/% ability to discriminate the cancers from others) respectively. 

their financials will be their first priority so until their financials are posted I'm not expecting to much aristotle news. But when it's ready. Be ready. Cause a tidal wave is coming. 

if they roll this out well with the right people on board and the proper execution this test could change the way people get tested for cancer and to detect cancer months to years early which can save thousands of lives yearly. A total paradigm shift in cancer detection technology. 

 

patience. 

<< Previous
Bullboard Posts
Next >>